Psychedelics consultants throughout scientific trials, psychotherapy and regulation have been reflecting on the challenges dealing with the sector since a webinar organised by the Worldwide Alliance of Psychological Well being Analysis Funders (IAMHRF) in late 2024. This commentary seems to be at the way forward for psychedelics as psychological well being remedy and offers suggestions for shifting the sector ahead.
This weblog has been co-authored by: Niall Boyce, Florence Butlen-Ducuing, Pim Cuijpers, Allan Younger and Anna Zecharia.
After a interval out within the chilly, the so-called “psychedelic renaissance” constructed up hopes that psychedelics—normally together with psychotherapy—may supply a brand new remedy paradigm for psychological well being circumstances. Nonetheless, vital issues concerning the high quality of analysis, together with problems with bias, led to the FDA declining to approve a remedy combining MDMA (which isn’t strictly a psychedelic) with psychotherapy. But, simply months later, Compass Pathways introduced that its first Part 3 trial of COMP360 psilocybin met its major endpoint—a statistically and clinically vital discount in despair signs at six weeks—demonstrating that, the place trial design meets regulatory requirements, progress stays potential.
Hope, as ever, have to be tempered by pragmatism. While it’s tempting to speak concerning the heyday of psychedelics analysis within the Fifties and 60s—which made vital contributions to understanding of the states induced by these compounds—the truth is, the problems the sector now faces (e.g. small trials, insufficient controls, the necessity to shield weak individuals) had been issues then too (see part 3).
These challenges are well-known, they’ve continued, and they won’t remedy themselves.
It’s potential for the sector to take the identical strategy to those points as Charles Dickens’s Mr Micawber took to his funds, and reside in hope that “one thing will flip up”. Nonetheless, this is able to be a missed alternative and a disservice to the sufferers who would possibly profit from psychedelic therapies. Due to this fact, on this commentary, we argue that the sector must be proactive in creating a consensus on the way in which ahead, and we provide 5 key areas for motion, with tangible options that we hope will get this dialogue began:
- Set a balanced tone
- Discover consensus on strategies
- Outline good analysis priorities
- Make clear the function of psychotherapy
- Put together well being programs
Are we actually in the midst of a psychedelic renaissance for our psychological well being?
1. Set a balanced tone
Embrace the promise of psychedelics with out overselling or shedding sight of scientific actuality.
While the therapeutic potential is important, psychedelics won’t ever be a cure-all. The fact is that if therapies are proven to be protected and efficient, they may most certainly profit a subgroup of people who find themselves experiencing intractable signs in particular circumstances, akin to despair and PTSD. The best way we discuss psychedelics issues.
Nonetheless, discussions about psychedelics tackle a distinct tone in comparison with different therapeutic modalities. A combination of fascination, warning, and hyperbole surrounds the sector – and we imagine that is having an unhelpful affect on analysis and sufferers. The social context of their ‘heyday’, their important disappearance from the analysis panorama, and their subsequent resurgence all appear to have formed the way in which we see psychedelics.
The origin of psychedelics analysis in Western tradition is traced to Arthur Heffter, who remoted mescaline from peyote cactus, itself introduced again from Mexico by Carl Lumholz. Advances in natural chemistry and pharmacology presently fueled broad exploration of psychoactive compounds, set towards a background of so-called ethnology research of indigenous rituals. The roots of the heyday (although after all this grew to become overtaken by the synthesis of LSD) are set in a broader context of scientific fascination with human consciousness. Certainly, the roots of the phrase psychedelic are within the Greek for ‘psyche – or soul – manifesting’. The present curiosity in psychedelics appears to be coinciding with a resurgence in curiosity in spirituality, notably in younger individuals.
Two issues occurred within the Nineteen Sixties to stem the tide of analysis into psychedelics: Schedule 1 classification (following a backlash towards rising leisure use of psychedelics) and a rise in medicines regulation following the thalidomide scandal. Each led to sensible restrictions on researchers’ capability to entry and use psychedelics, alongside a lack of respectability of the analysis itself. Scientific exercise dropped off a cliff.
Its resurgence has been linked to advocacy inside the scientific neighborhood: a Swiss Academy of Medical Sciences Symposium that introduced the small analysis neighborhood collectively, and the institution of the Heffter Analysis Institute (HRI) with the aim of rebuilding the analysis base. It was not potential for governments to fund psychedelics analysis, so the panorama grew to become dominated by HRI funding till psychedelics analysis once more entered the mainstream. The legacy of advocacy-driven funding stays.
We wish to see the dialogue of psychedelics retain its tone of fascination, however to stability this with scientific realism – and to recognise the sociocultural heritage of psychedelic compounds that play an necessary function in religious practices in indigenous cultures world wide. We should always embrace our fascination with psychedelics in these analysis settings – however we ought to be specific that that is a part of a curiosity about human consciousness and the religious expertise, not use psychedelics analysis as a proxy. Maybe elevating the respectability and acceptability of that sort of analysis in psychological well being and the neurosciences (respectfully, with companions in different fields and cultures) will assist us separate this facet of psychedelics analysis from investigations into therapeutic potential that should concentrate on the neutral institution of security and efficacy.
We wish to see the dialogue of psychedelics retain its tone of fascination, however to stability this with scientific realism.
2. Discover consensus on strategies
Sort out the trial design points that will compromise the security and efficacy of psychedelics.
The a number of sources of variability in psychedelics trials muddy the interpretation of therapeutic impact in human trials. Regulators want the identical stage of robustness to reveal security and efficacy as every other drug. Due to this fact, addressing examine design points is a precedence to help improvement and approval.
The problem is in how these variables will be managed and remoted, while being pragmatic concerning the subjective nature of the psychedelic expertise. Variables will be grouped into 4 primary classes:
- security and efficacy of the psychedelic;
- security and efficacy of the related psychotherapy;
- participant mindset and expectation; and
- therapist/trialist mindset and stage of experience, which may affect interactions with the participant.
A basic problem which additional hampers discerning sign from noise is that trials are typically small and underpowered.
Concerning establishing security and efficacy of the drug, a acutely aware affected person shall be conscious that they’re taking a psychedelic. Which means that the same old strategy to placebo-controlled and double-blinded trials isn’t potential; or to place it one other manner, you would possibly or may not know you probably have taken an SSRI, however you’ll nearly actually know you probably have taken a dose of LSD.
Additional issues come up in the case of understanding whether or not the psychotherapeutic part of psychedelic therapies is efficient. First, the psychotherapeutic routine utilized in psychedelic remedy (preparation – security throughout expertise – integration) advanced based mostly on scientific observations in the course of the Fifties and Nineteen Sixties, and is simply utilized in mixture with psychedelics; it isn’t a validated standalone psychotherapeutic strategy. Moreover, there’s appreciable variability in how this psychotherapy is delivered inside and throughout trials, together with the extent of experience of the therapist. Lastly, we simply don’t know whether or not validated therapies akin to CBT or short-term psychodynamic psychotherapy are applicable, so it’s not potential to substitute in a type of remedy that’s extra simply managed with out additional research.
Then there’s the necessary incontrovertible fact that members who participate in psychedelics trials might begin out with a desire or excessive expectation; this additional complicates the issue with placebo management, because the affected person who doesn’t obtain a drug with acute psychotropic results will comprehend it, and their consequence would possibly replicate dissatisfaction with their allocation. This may be compounded by therapists who present a bias (acutely aware or unconscious) in the direction of psychedelics if it influences their behaviour and strategy to the participant.
Desk 1. Potential options for addressing variability in psychedelic-assisted psychotherapy trials.
| Supply of variability | Potential options for dialogue and improvement with the sector |
| Security and efficacy of the psychedelic
|
Recognising that blinding isn’t potential for top doses of psychedelics:
Revisit low dose psycholytic approaches, that minimise the psychedelic impact to allow blinding via conventional placebo strategies. Restrict trial members to the supposed affected person inhabitants – i.e. prioritise extreme sufferers with intractable signs. The excessive scientific want would allow security to be prioritised in a short-term examine, with a decrease threshold for efficacy. Long run follow-up for each security and efficacy ought to be constructed into examine design to evaluate this affected person inhabitants and help targeted HTA decision-making. Guarantee variety in trial members to enhance actual world validity. |
| Security and efficacy of the psychotherapy
|
Design trials with a rationally designed remedy management. That’s, use a standardised management psychotherapy protocol that ensures a protected expertise, and evaluate this to ‘lively’ protocols which are designed to help integration of the expertise, or are already validated protocols (e.g. short-term psychodynamic remedy, CBT).
Guarantee open manuals for psychotherapeutic protocols utilized in trials. Set a minimal expertise stage for therapist eligibility. Discover implications of separate regulatory pathways e.g. within the reporting of potential long-term adversarial results of psychotherapy. |
| Participant mindset
|
Index sufferers by ‘psychedelic desire/expectations’ to not less than monitor this variable.
Exclude members with earlier expertise of psychedelics. |
| Therapist/trialist mindset
|
Guarantee all stakeholders in a psychedelic trial have a shared understanding of the significance of strong trial design and execution, together with how sources of variability work together.
Make sure that psychotherapy protocols utilized in trials make ‘therapeutic sense’ to the therapist—together with participating psychotherapists in co-designing trials. Set up clear codes of conduct, together with battle of curiosity declarations. Introduce blinding for outcomes evaluation. |
Lastly, variability in approaches to review design are a barrier to demonstrating security and efficacy at scale: standardising design is a manner to enhance consistency. The European Medicines Company (EMA) has additionally acknowledged the necessity for methodological innovation on this house. Of their 2024 multi-stakeholder workshop, they emphasised the significance of adapting conventional trial frameworks to account for the distinctive traits of psychedelics, and highlighted the potential worth of worldwide collaboration to harmonise approaches throughout jurisdictions. The EMA additionally finalised a new Guideline on the Scientific Investigation of Medicinal Merchandise for Despair, which incorporates for the primary time a devoted part on psychedelics—formalising greatest practices for his or her analysis in despair trials. The COMP360 Part 3 trial is an early indication that with rigorous trial design and outlined affected person populations, psychedelic compounds can meet standard regulatory requirements.
Unpicking these sources of variability isn’t simple, however we expect it’s potential—and there are clear examples of motion in the direction of deliberation, resolution and motion in live performance throughout the sector, probably together with checkpoints on the stage of funders and journals. In desk 1 we’ve urged some tangible approaches (that might should be enacted together) within the hope that this may assist information scientific dialogue.
Regulators want the identical stage of robustness in psychedelics analysis to reveal security and efficacy as every other drug.
3. Outline good analysis priorities
Goal the essential questions that may really transfer the sector ahead.
Excessive curiosity in psychedelics gives a chance for funding in analysis that has the potential to considerably advance the sector if these questions will be recognized and addressed with targeted consideration. These questions relate to security and efficacy, mechanism of motion, the broader software of psychedelics, the function of animal research, and analysis on the psychedelic expertise itself.
Latest public and institutional funding—together with over USD $50 million from the State of Texas for ibogaine analysis, new U.S. Division of Protection and Veterans Affairs grants for MDMA-assisted remedy, a €6.5 million (equal to over USD $7.5 million) Horizon Europe award for the EU-wide PsyPal trial in palliative care, and Australia’s insurer-backed funding for psychedelic remedy—alerts rising world dedication to psychedelic innovation, offered it’s grounded in sturdy, high-quality proof.
In desk 2, we’ve highlighted what we imagine to be essentially the most urgent and promising avenues for analysis.
*Desk 2. Precedence analysis questions, by theme.
| Theme | Precedence analysis questions, for dialogue and improvement with the sector |
| Security & efficacy | What are the optimum remedy protocols? (dose, length, frequency)
What’s the length of the therapeutic impact publish remedy? Is psychotherapy an integral a part of psychedelic remedy, and in that case – what sort of psychotherapy? Can scientific options and/or organic biomarkers predict efficacy and/or security? Can scientific options and/or organic biomarkers help personalisation of psychedelic remedy? Does the concomitant administration of different (generally prescribed) psychiatric medicines have an effect on the security and efficacy of psychedelics and vice versa? If that’s the case, what are the scientific implications (e.g. discontinuation, concomitant use) and the way ought to this be mirrored within the product data? |
| Mechanism of motion in intractable despair and PTSD | How would possibly neural pathways implicated in different pharmacological therapeutic methods contribute to the scientific motion of psychedelics? What are the neural mechanisms for psychedelic therapeutic impact on the mobile and community stage?
Are the acute dissociative/hallucinogenic results crucial for long-lasting therapeutic efficacy? And if not, would it not be potential to develop psychedelics that might be efficient with out the possibly difficult ‘journey’ expertise? How does the psychotherapy part of psychedelic assisted remedy work? Nonetheless, we recognise that figuring out the mechanism of motion of psychotherapy (in any setting) is fraught with challenges, and would require vital analysis funding. |
| Potential software of psychedelics in different scientific indications.
|
What’s the therapeutic potential of psychedelics in neurodegenerative circumstances akin to Alzheimer’s illness?
What’s the therapeutic potential of psychedelics in palliative care, notably when ordinary therapies don’t assist decreasing signs of tension, despair, or existential misery What are the neural mechanisms for psychedelic therapeutic impact throughout a variety of different potential scientific indications, on the mobile and community stage? How can we guarantee security and efficacy in these settings, with learnings from trial design challenges so far? |
| Function of animal research
|
Which animal fashions have predictive validity for human research of psychedelics, and what points of the expertise or therapeutic profit are they a proxy for?
Which animal fashions can help investigation into neural mechanisms? Which animal research lack validity and will not be acceptable within the subject? Might this steerage be expanded to assist form psychedelics analysis? |
| The psychedelic expertise | What are the most effective measurements (goal and subjective) to quantify and describe the psychedelic expertise? What’s the function of qualitative analysis within the subject?
Recognising that the psychedelic expertise has roots in indigenous religious observe, do we’ve the interdisciplinary experience and collaborations (together with companions akin to from indigenous tradition, philosophy, ethics, faith) to develop the sectorin investigating religious/non secular expertise because it pertains to the human expertise—to which means, goal, resilience and wellbeing? |
Analysis funding has the potential to considerably advance the sector, however provided that we prioritise a very powerful questions.
4. Make clear the function of psychotherapy
Resolve the regulatory gray zone.
Top quality trials that allow confidence in security and efficacy knowledge ought to help the psychedelic journey via customary approval processes, and progress right here will essentially be linked to efforts to enhance trial high quality and consistency as we’ve outlined in part 2. Nonetheless, a further complicating issue is that purposes are for psychedelic-assisted psychotherapy—and psychotherapy falls past the remit of regulatory businesses.
In precept, this isn’t an issue. If a psychotherapy is deemed to be an integral a part of drug remedy, this may very well be represented on the drug label – this has been carried out beforehand. Nonetheless, this has not but been established for psychedelic remedy. Regulators must know whether or not psychotherapy is integral, or whether or not it ought to be dealt with as part of a extra world security help framework. To deal with this, a scientific trial with a factorial design would possible be wanted to permit an correct analysis of the efficacy of each parts based mostly on respective related endpoints.
Is psychotherapy an integral a part of psychedelic remedy?
5. Put together well being programs
Guarantee readiness for implementation.
A lot of the dialogue within the subject so far has been about every part as much as the approval course of, however not a lot past it. The therapeutic advantage of psychedelics will solely be realised when they’re utilized in the correct affected person populations in the actual world. So whilst we grapple with security and efficacy, we should additionally suppose forward to potential implementation in case they show to be efficient.
We all know that lack of long-term knowledge on security and effectiveness has impacted HTA suggestions, so it’s clearly essential to combine this sort of knowledge assortment (by way of part 4 trials) into analysis programmes with the intention of supporting HTA organisations to make knowledgeable selections. To have the ability to assess the potential added worth of these therapies in comparison with our present therapeutic arsenal, HTA our bodies would wish to know additionally how psychedelics would slot in present remedy paradigms and underneath which scientific setting. We aren’t conscious whether or not HTA organisations have been engaged in stakeholder discussions about psychedelics, however there is a chance to make sure the analysis neighborhood understands their wants and the way this would possibly affect analysis design. As with regulators, early dialogue with HTA organisations is essential to make sure that trials are aligned with necessities.
It’s also not clear whether or not present scientific service fashions, services, coaching, and staffing ranges in any geographical setting are able to help implementation of psychedelics-assisted remedy in well being care programs. Portugal has revealed its first multidisciplinary scientific steerage on psychedelic therapies, developed by skilled associations throughout psychiatry, psychology, pharmacy, and ethics—a proactive step towards real-world readiness. There’s a potential difficulty of fairness of entry, and the danger of broad variation each inside and between nations in provision of remedy (together with laws to help entry), and protected, moral approaches to safety of people in acutely weak states.
What must occur in the actual world for us to begin implementing psychedelic-assisted remedy in well being care programs?
Closing ideas
Funding in psychedelics analysis have to be targeted on the questions that may take the sector ahead – not on excessive quantity, low return analysis.
As therapeutic brokers, psychedelics supply hope to the sub-group of sufferers who discover no aid via present remedy methods. It’s our view that such research ought to concentrate on these sufferers, embedding their wants into examine design and long-term comply with as much as rigorously set up security and efficacy of the drug and related psychotherapy. This can permit regulators to precisely specify scientific particulars of psychotherapy – thus clearing the runway for regulatory approval. To do that, we have to prioritise massive, high-quality trials that may set up security and efficacy.
Approval and adoption are completely different challenges: we aren’t satisfied that there was adequate HTA organisation involvement with this dialogue so far, and wish to see this variation. HTA organisations make selections towards the care presently obtainable – nonetheless, the purpose is that the sufferers who stand to profit from psychedelics don’t reply to those choices. Given the healthcare programs price of psychedelic-assisted psychotherapy is more likely to be larger than a drug-only strategy, there’s a danger that these therapies shall be systematically deprived until the costing is tailor-made to the supposed affected person inhabitants.
Psychedelics will help us discover really fascinating questions on human consciousness, and what it means to be human. These questions can’t be the area of 1 subject – be that neuroscience, philosophy or religious traditions from internationally – however maybe working collectively we may set up a brand new subject that balances experimental approaches with different types of enquiry and proof.
Psychedelic-assisted remedy ought to goal individuals with troublesome to deal with circumstances, who haven’t benefitted from different therapies.
Assertion of curiosity
This weblog has been co-authored by a bunch of consultants who participated in a webinar organised by the Worldwide Alliance of Psychological Well being Analysis Funders (IAMHRF) in late 2024:
- Niall Boyce “I’m Head of Data and Measurement at Wellcome, and haven’t any different pursuits to declare.”
- Florence Butlen-Ducuing “I’m a psychiatrist working within the psycho-oncology Unit at Gustave Roussy Most cancers Campus Grand Paris, and within the INSERM Moods analysis Unit, at Paris Saclay College. I’ve no pursuits to declare.”
- Pim Cuijpers “I’m Professor Emeritus on the Vrije Universiteit Amsterdam, and I’ve no pursuits to declare.”
- Allan Younger – Declaration of Pursuits (PDF)
- Anna Zecharia “I’m Director, Programmes and Partnerships at IAMHRF and I’ve no pursuits to declare.”
References
Axios. (2025). Texas to spend tens of millions on psychedelic analysis. Axios Native – Dallas. https://www.axios.com/native/dallas/2025/06/26/texas-ibogaine-psychedelic-veterans-ptsd
Celidwen, Y., Redvers, N., Githaiga, C. et al. (2023). Moral ideas of conventional Indigenous drugs to information western psychedelic analysis and observe. Lancet Reg Well being Am 18, 100410. https://doi.org/10.1016/j.lana.2022.100410
Compass Pathways. (2025). Compass Pathways efficiently achieves major endpoint in first Part 3 trial evaluating COMP360 psilocybin for treatment-resistant despair. Compass Pathways Newsroom. https://ir.compasspathways.com/Information–Occasions-/information/news-details/2025/Compass-Pathways-Efficiently-Achieves-Main-Endpoint-in-First-Part-3-Trial-Evaluating-COMP360-Psilocybin-for-Therapy-Resistant-Despair/default.aspx
Cristea, I.A., Cuijpers, P., Halvorsen, J.Ø. (2024). The psychotherapy in MDMA-assisted psychotherapy. JAMA Psychiatry 81, 1053–1054. https://doi.org/10.1001/jamapsychiatry.2024.2887
European Well being and Digital Government Company. (2024). PsyPal challenge launch occasion within the EP: “Psychedelics in palliative care”. HaDEA Occasions. https://hadea.ec.europa.eu/occasions/psypal-project-launch-event-ep-psychedelics-palliative-care-2024-04-09_en
European Medicines Company. (2006). Guideline on the non-clinical investigation of the dependence potential of medicinal merchandise. EMEA/CHMP/SWP/94227/2004. https://www.ema.europa.eu/en/paperwork/scientific-guideline/guideline-non-clinical-investigation-dependence-potential-medicinal-products_en.pdf
European Medicines Company. (2024). Report: EMA multi-stakeholder workshop on psychedelics – In direction of an EU regulatory framework. European Medicines Company. https://www.ema.europa.eu/en/paperwork/report/report-ema-multi-stakeholder-workshop-psychedelics_en.pdf
European Medicines Company. (2024). Selincro: EPAR – Product Data. European Medicines Company. https://www.ema.europa.eu/en/paperwork/product-information/selincro-epar-product-information_en.pdf
European Medicines Company. (2025). Guideline on the Scientific Investigation of Medicinal Merchandise for the Therapy of Despair. https://www.ema.europa.eu/en/paperwork/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf
Geyer, M.A. (2024). A quick historic overview of psychedelic analysis. Biol Psychiatry Cogn Neurosci Neuroimaging 9, 464–471. https://doi.org/10.1016/j.bpsc.2023.11.003
Corridor, W.D. (2021). Why was early therapeutic analysis on psychedelic medication deserted? Psychol Med 51, 1–9. https://doi.org/10.1017/S0033291721004207
Kazdin, A.E. (2007). Mediators and mechanisms of change in psychotherapy analysis. Annu Rev Clin Psychol 3, 1–27. https://doi.org/10.1146/annurev.clinpsy.3.022806.091432
Khazan, O. (2024). The weak science behind psychedelics. The Atlantic. https://www.theatlantic.com/concepts/archive/2024/10/psychedelics-medicine-science/680286/
Kishon, R., Modlin, N.L., Cycowicz, Y.M. et al. (2024). A speedy narrative overview of the scientific evolution of psychedelic remedy in scientific trials. npj Ment Well being Res 3, 33. https://doi.org/10.1038/s44184-024-00068-9
Lykos Therapeutics. (2024). Lykos Therapeutics pronounces full response letter for midomafetamine capsules for PTSD. Lykos Therapeutics Newsroom. https://information.lykospbc.com/2024-08-09-Lykos-Therapeutics-Pronounces-Full-Response-Letter-for-Midomafetamine-Capsules-for-PTSD
McNamara, P., Newsome, W., Linkenhoker, B. & Grafman, J. (2024). Neuroscientists should not be afraid to review faith. Nature 631, 25–27. https://doi.org/10.1038/d41586-024-02153-7
Army.com (2024). VA funds Ivy League analysis on MDMA remedy for post-traumatic stress, alcohol abuse.https://www.navy.com/daily-news/2024/12/03/va-funds-ivy-league-research-mdma-treatment-post-traumatic-stress-alcohol-abuse.html
Army Instances. (2025). DoD commits $9.8 million to review psychedelics for lively‑obligation troops.https://www.militarytimes.com/information/your-military/2025/03/17/dod-commits-98-million-to-study-psychedelics-for-active-duty-troops
Nationwide Institute for Well being and Care Excellence. (2024). Evaluation resolution: Esketamine nasal spray for treatment-resistant despair (TA854). NICE Know-how Appraisal Steerage. https://www.good.org.uk/steerage/ta854/sources/review-decision-pdf-17410403923909
Subsequent Buyers. (2025). Emyria studies promising PTSD restoration knowledge 6 months after remedy. Subsequent Buyers. Retrieved from https://nextinvestors.com/quick-takes/emd-reports-promising-ptsd-recovery-data-6-months-after-treatment/
PAREA. (2024). Portugal launches multidisciplinary scientific steerage on psychedelic therapies. PAREA Information. https://parea.eu/parea-news/portugal-launches-multidisciplinary-clinical-guidance-on-psychedelic-therapies
PAREA. (2025). Czech Republic passes legislation enabling entry to psilocybin remedy. PAREA Information. Retrieved from https://parea.eu/parea-news/czech-republic-psilocybin-law-passed-2025
Rucker, J.J.H., Iliff, J., & Nutt, D.J. (2018). Psychiatry & the psychedelic medication. Previous, current & future. Neuropharmacology 142, 200–218. https://doi.org/10.1016/j.neuropharm.2017.12.040
Winkelman, M.J., Szabo, A., Frecska, E. (2023). The potential of psychedelics for the remedy of Alzheimer’s illness and associated dementias. Eur Neuropsychopharmacol 76, 3–16. https://doi.org/10.1016/j.euroneuro.2023.07.003
